Other languages Medivir AB

Equities

MVIR B

SE0020181014

Market Closed - Nasdaq Stockholm Other stock markets 11:29:32 2024-05-31 am EDT			5-day change	1st Jan Change
3.23 ^SEK	-.--%		+18.32%	+13.33%

May. 07	Medivir Aktiebolag Approves Board Appointments	CI
Apr. 30	Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024	May. 30
Medivir to present at Redeye Growth Day	May. 30
Medivir : acute;s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	May. 23
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	May. 23
Resolutions at the Annual General Meeting in Medivir on 7 May 2024	May. 07
Medivir Aktiebolag Approves Board Appointments	May. 07
BioStock: Double thumbs up for Medivir from the FDA	May. 03
Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024	Apr. 30
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024	Apr. 30
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30
Medivir brings the Q1 webcast forward to 10 a.m. on April 30	Apr. 29
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI	Apr. 29
Medivir AB Provides Update from Positive Type C Meeting with the FDA; Preparations for Enhanced Phase 2b in HCC with Fostrox + Lenvima	Apr. 29
BioStock: Medivir optimizes study design after meeting FDA	Apr. 26
Medivir Gets Two US FDA Designations for MIV-711	Apr. 25
Medivir : FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease	Apr. 25
FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease	Apr. 25
FDA Grants Medivir AB´S MIV-711 Rare Pediatric Disease Designation for the Treatment of Legg-Calvé-Perthes Disease	Apr. 25
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue	Apr. 23
BioStock: Medivir's partner makes clinical progress in veterinary project	Apr. 19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Medivir AB

Equities

MVIR B

SE0020181014

Other languages

Filters